Prediction of pyrotinib exposure based on physiologically-based pharmacokinetic model and endogenous biomarker

Pyrotinib, a novel irreversible epidermal growth factor receptor dual tyrosine kinase inhibitor, is mainly (about 90%) eliminated through cytochrome P450 (CYP) 3A mediated metabolism in vivo. Meanwhile, genotype is a key factor affecting pyrotinib clearance and 4β-hydroxycholesterol is an endogenous...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Miao, Yu, Zhiheng, Yao, Xueting, Lei, Zihan, Zhao, Kaijing, Wang, Wenqian, Zhang, Xue, Chen, Xijing, Liu, Dongyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543720/
https://www.ncbi.nlm.nih.gov/pubmed/36210839
http://dx.doi.org/10.3389/fphar.2022.972411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543720/
https://www.ncbi.nlm.nih.gov/pubmed/36210839
http://dx.doi.org/10.3389/fphar.2022.972411

Ejemplares similares